MCLEAN, VA & JAKARTA, INDONESIA — May16, 2025 — Perthera, The Therapeutic Intelligence Company, and PathGen Diagnostik Teknologi, Indonesia’s premier molecular diagnostics provider, have announced a strategic partnership to democratize access to high quality cancer care across Indonesia. By combining Perthera’s AI-driven treatment intelligence with PathGen’s extensive local infrastructure and clinical expertise, the collaboration aims to integrate molecular profiling, bioinformatics, and evidence-based decision support into Indonesia’s oncology treatment landscape, significantly improving patient outcomes while reducing healthcare costs.
Partnership Overview
- Advanced Molecular Profiling: Implementation of next-generation sequencing (NGS) and proteomic analyses to generate comprehensive tumor profiles.
- AI-Driven Therapeutic Recommendations: Deployment of Perthera’s AI precision oncology expertise for locally tailored, evidence-based treatment recommendations using multi-omic data.
- Capacity Building and Training: Development and delivery of educational programs for oncologists, pathologists, and clinical teams to integrate precision medicine into routine practice.
- Data Integration for Policy and Research: Consolidation of clinical and molecular data to inform national healthcare policies, facilitate local research, and contribute to global oncology datasets.
“At Perthera, we are dedicated to transforming cancer care through our AI-powered Precision Oncology Platform that precisely matches cancer patients with therapeutic treatment options specific to their individual cancer,” said Donna Tuths, CEO of Perthera, Inc. “By partnering with PathGen Diagnostik Teknologi, we will bring our cutting-edge technology to Indonesia, enabling physicians to select the most appropriate diagnostic and therapeutic pathways for each patient. Together, we will make a significant impact on cancer care in the region.”
“Having walked the journey from diagnosis to remission myself, I know all too well the uncertainty and fear that patients face,” said Dr. Susanti, CEO PathGen Diagnostik Teknologi. “This partnership is more than a technological advance—it’s a lifeline. By harnessing Perthera’s AI-driven insights with PathGen’s local expertise, we can guide each patient toward the most effective therapies from the very start. As a survivor, I am committed to ensuring that no one in Indonesia endures cancer without hope or access to the best possible treatment.”
Impact and Objectives
- Enhanced Clinical Outcomes: Transition from empirical treatment selection to targeted therapy approaches that improve progression-free and overall survival rates.
- Cost Efficiency: Minimize ineffective treatment regimens, reduce patient out-of pocket expenditures, and alleviate pressure on the national health insurance system (BPJS Kesehatan).
- Healthcare System Strengthening: Establish a scalable precision oncology framework aligned with Indonesia’s healthcare modernization initiatives
Under the terms of the agreement, Perthera and PathGen will develop a comprehensive precision oncology program combining Perthera’s expertise in precision oncology, technical support, and global research networks with PathGen’s nationwide laboratory infrastructure, clinical integration capabilities, and patient-centric services.
About Perthera, Inc. Perthera, The Therapeutic Intelligence Company, specializes in AI driven precision oncology. The company integrates multi-omic data—from partners including Tempus, Foundation Medicine, Caris, and Guardant—to deliver ranked treatment recommendations tailored to each patient’s tumor profile. Deployed in over 600 cancer centers and utilized by more than 1,500 oncologists worldwide, Perthera’s platform has demonstrated a 2.4-fold improvement in progression-free survival in peer-reviewed studies. For further information, visit www.perthera.com.
About PathGen Diagnostik Teknologi PathGen Diagnostik Teknologi is Indonesia’s leading molecular diagnostics provider, dedicated to advancing personalized medicine through state of-the-art testing and compassionate patient care. Under the leadership of Dr. Susanti, PathGen offers comprehensive molecular profiling services and supports clinical decision-making with a focus on enhancing patient outcomes. For additional details, visit pathgen.co.id.